Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 6/2019

01-06-2019 | Imipenem | Original Article

In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015–2016

Authors: Irene Galani, Maria Souli, Konstantina Nafplioti, Panagiora Adamou, Ilias Karaiskos, Helen Giamarellou, Anastasia Antoniadou, On Behalf Of The Study Collaborators

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 6/2019

Login to get access

Abstract

Relebactam is a β-lactamase inhibitor of class A and class C β-lactamases, including carbapenemases. We evaluated the ability of relebactam to restore imipenem susceptibility against a collection of Klebsiella pneumoniae isolates from Greek hospitals. We tested 314 non-MBL carbapenemase-producing K. pneumoniae consecutive clinical strains isolated from unique patients at 18 hospitals in Greece, between November 2014 and December 2016. Susceptibility testing of imipenem, imipenem-relebactam, meropenem, doripenem, gentamicin, and colistin was performed using broth microdilution. Additionally, MICs of ceftazidime-avibactam, fosfomycin, and tigecycline were determined by MIC Test Strips. MICs were interpreted per EUCAST breakpoints. Imipenem-relebactam MICs were interpreted using the breakpoints proposed for imipenem. Carbapenemase genes were detected using PCR. Whole genome sequencing was performed for selected isolates. Imipenem-relebactam inhibited 98.0% of the KPC-producing isolates at ≤ 2 mg/L (MIC50/90, 0.25/1 mg/L) and was considerably more active than imipenem (MIC50/90, 32/> 64 mg/L). Reduced activity of imipenem-relebactam was rarely detected (2%) and was associated with chromosomal factors (ompK35 disruption and/or mutated ompK36). Only ceftazidime-avibactam showed in vitro activity comparable to imipenem-relebactam (99.6% susceptible). Relebactam provided only weak potentiation of imipenem activity against K. pneumoniae with class D OXA-48-like enzymes. Relebactam exhibited strong potential for restoring the in vitro activity of imipenem against KPC-producing K. pneumoniae, lowering the imipenem MIC50 and MIC90 from 32 to 0.25 mg/L, and from > 64 to 1 mg/L, respectively. Production of KPC carbapenemase represents the main cause of carbapenem resistance among K. pneumoniae in Greek hospitals (66.5%), and this carbapenemase appears to be very well inhibited by relebactam.
Literature
5.
go back to reference Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA (2018) Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-β-lactamase inhibitor combinations. Drugs 78:65–98. https://doi.org/10.1007/s40265-017-0851-9 CrossRefPubMed Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA (2018) Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-β-lactamase inhibitor combinations. Drugs 78:65–98. https://​doi.​org/​10.​1007/​s40265-017-0851-9 CrossRefPubMed
6.
go back to reference Galani I, Karaiskos I, Karantani I, Papoutsaki V, Maraki S, Papaioannou V, Kazila P, Tsorlini H, Charalampaki N, Toutouza M, Vagiakou H, Pappas K, Kyratsa A, Kontopoulou K, Legga O, Petinaki E, Papadogeorgaki H, Chinou E, Souli M, Giamarellou H, On Behalf Of The Study Collaborators (2018) Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016. Euro Surveil; 23(31). https://doi.org/10.2807/1560-7917.ES.2018.23.30.1700775 b Galani I, Karaiskos I, Karantani I, Papoutsaki V, Maraki S, Papaioannou V, Kazila P, Tsorlini H, Charalampaki N, Toutouza M, Vagiakou H, Pappas K, Kyratsa A, Kontopoulou K, Legga O, Petinaki E, Papadogeorgaki H, Chinou E, Souli M, Giamarellou H, On Behalf Of The Study Collaborators (2018) Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016. Euro Surveil; 23(31). https://​doi.​org/​10.​2807/​1560-7917.​ES.​2018.​23.​30.​1700775 b
7.
go back to reference Nafplioti K, Galani I, Moraitou E, Giannopoulou P, Chra V, Damala M, Vogiatzakis E, Trikka-Graphakos E, Baka V, Prifti E, Souli M (2017) Prevalence of 16S rRNA methylase genes in gram negative isolates in Athens metropolitan area in a six month period. In 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 2017, P0208 Nafplioti K, Galani I, Moraitou E, Giannopoulou P, Chra V, Damala M, Vogiatzakis E, Trikka-Graphakos E, Baka V, Prifti E, Souli M (2017) Prevalence of 16S rRNA methylase genes in gram negative isolates in Athens metropolitan area in a six month period. In 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 2017, P0208
8.
go back to reference Clinical and Laboratory Standards Institute (2015) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard —Tenth Edition. CLSI document M07-A10. Wayne, PA Clinical and Laboratory Standards Institute (2015) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard —Tenth Edition. CLSI document M07-A10. Wayne, PA
9.
go back to reference European Society of Clinical Microbiology and Infectious Diseases [Internet]. Clinical breakpoints version 8.0. In European Committee on Antimicrobial Susceptibility Testing. Växjö: EUCAST; 2018. Available from: http://www.eucast.org European Society of Clinical Microbiology and Infectious Diseases [Internet]. Clinical breakpoints version 8.0. In European Committee on Antimicrobial Susceptibility Testing. Växjö: EUCAST; 2018. Available from: http://​www.​eucast.​org
10.
go back to reference Lampri N, Galani I, Poulakou G, Katsarolis I, Petrikkos G, Giamarellou H, Souli M (2012) Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. J Antimicrob Chemother 67:2424–2428. https://doi.org/10.1093/jac/dks215 CrossRefPubMed Lampri N, Galani I, Poulakou G, Katsarolis I, Petrikkos G, Giamarellou H, Souli M (2012) Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. J Antimicrob Chemother 67:2424–2428. https://​doi.​org/​10.​1093/​jac/​dks215 CrossRefPubMed
12.
go back to reference García-Fernández A, Miriagou V, Papagiannitsis CC, Giordano A, Venditti M, Mancini C, Carattoli A (2010) An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. Αntimicrob Agents Chemother 54:4178–4184. https://doi.org/10.1128/AAC.01301-09 CrossRef García-Fernández A, Miriagou V, Papagiannitsis CC, Giordano A, Venditti M, Mancini C, Carattoli A (2010) An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. Αntimicrob Agents Chemother 54:4178–4184. https://​doi.​org/​10.​1128/​AAC.​01301-09 CrossRef
14.
go back to reference Young K, Raghoobar SL, Hairston NN, Painter RE, Racine F, Dorso KL, Park YW, Ogawa AM, Wisniewski D, Hermes J, Blizzard TA, Hammond ML, Motyl MR (2010) In vitro activity of the class a and C β-lactamase inhibitor MK-7655. In: Posters of the fiftieth Interscience conference on antimicrobial agents and chemotherapy, Boston, MA, USA. Poster F1–2139. American Society for Microbiology, Washington, DC, USA Young K, Raghoobar SL, Hairston NN, Painter RE, Racine F, Dorso KL, Park YW, Ogawa AM, Wisniewski D, Hermes J, Blizzard TA, Hammond ML, Motyl MR (2010) In vitro activity of the class a and C β-lactamase inhibitor MK-7655. In: Posters of the fiftieth Interscience conference on antimicrobial agents and chemotherapy, Boston, MA, USA. Poster F1–2139. American Society for Microbiology, Washington, DC, USA
17.
go back to reference Haidar G, Clancy CJ, Chen L, Samanta P, Shields RK, Kreiswirth BN, Nguyen MH (2017) Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant rnterobacteriaceae. Antimicrob Agents Chemother 61. https://doi.org/10.1128/AAC.00642-17 Haidar G, Clancy CJ, Chen L, Samanta P, Shields RK, Kreiswirth BN, Nguyen MH (2017) Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant rnterobacteriaceae. Antimicrob Agents Chemother 61. https://​doi.​org/​10.​1128/​AAC.​00642-17
19.
go back to reference Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN (2017) Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in enterobacteriaceae. Antimicrob Agents Chemother 61(11). https://doi.org/10.1128/AAC.01443-17 Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN (2017) Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in enterobacteriaceae. Antimicrob Agents Chemother 61(11). https://​doi.​org/​10.​1128/​AAC.​01443-17
Metadata
Title
In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015–2016
Authors
Irene Galani
Maria Souli
Konstantina Nafplioti
Panagiora Adamou
Ilias Karaiskos
Helen Giamarellou
Anastasia Antoniadou
On Behalf Of The Study Collaborators
Publication date
01-06-2019
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 6/2019
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-019-03517-y

Other articles of this Issue 6/2019

European Journal of Clinical Microbiology & Infectious Diseases 6/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.